Melanocortin Receptor Agonist
PT-141 (Bremelanotide) Research Peptide
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors (MC1R, MC3R, MC4R, MC5R). It is supplied as a lyophilized powder for laboratory research applications.
Compound identity
- Name
- PT-141
- Class
- Melanocortin Receptor Agonist
- CAS number
- 189691-06-3
- Molecular formula
- C50H68N14O10
- Also known as
- Bremelanotide, PT141, Melanocortin Receptor Peptide
- Sequence
- Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Research context
PT-141 (CAS 189691-06-3, molecular formula C50H68N14O10) is derived from the endogenous peptide alpha-MSH (alpha-melanocyte-stimulating hormone) through cyclization and modification. The compound is a cyclic heptapeptide containing a D-phenylalanine residue at position 4 and an N-terminal acetyl-norleucine. Its melanocortin receptor binding profile has been characterized in receptor pharmacology studies, with affinity for MC3R and MC4R subtypes that are expressed in the central nervous system.
The melanocortin receptor family (MC1R–MC5R) has been investigated in preclinical and clinical research contexts. MC4R in particular has been the focus of studies examining its role in physiological regulation, as it is expressed in hypothalamic nuclei and other CNS regions. PT-141's activity at melanocortin receptors has been studied in animal models and has also been evaluated in human clinical trials — the compound received FDA approval in 2019 as Vyleesi for a specific indication, making it one of the few peptides with both a research literature and a regulatory history.
As a research reagent, PT-141 is used in receptor pharmacology studies examining melanocortin signaling. DMV Research supplies PT-141 as a lyophilized powder with per-batch third-party Certificate of Analysis confirming identity and purity for research use. Not approved for human self-administration in research contexts.
Frequently asked questions
What is PT-141?+
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist. CAS 189691-06-3. It binds non-selectively to MC1R, MC3R, MC4R, and MC5R. It is used in receptor pharmacology research as a tool compound for studying melanocortin signaling.
What is the structure of PT-141?+
PT-141 has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is a cyclic heptapeptide with a lactam bridge between the Asp and Lys residues, an N-terminal acetyl group, and a D-phenylalanine at position 4. Molecular formula C50H68N14O10, CAS 189691-06-3.
Is PT-141 approved for human use?+
Bremelanotide (the INN for PT-141) received FDA approval in 2019 under the brand name Vyleesi for a specific therapeutic indication. However, as supplied by DMV Research, PT-141 is for laboratory and research use only, not for self-administration or human therapeutic use outside of an approved clinical context.
What purity is the PT-141 research peptide?+
Each batch is independently tested to 99%+ purity by third-party laboratories, with a Certificate of Analysis available per batch.
Research use only
All products are intended for laboratory and research use only (RUO) and are not for human consumption, ingestion, or any in-vivo use.
The statements on this page have not been evaluated by the FDA. PT-141 is not intended to diagnose, treat, cure, or prevent any disease. Content is provided for laboratory research reference only.